NeoGenomics reported its third‑quarter 2025 results, posting total revenue of $188 million, a 12% year‑over‑year increase. Clinical revenue grew 18%, while next‑generation sequencing (NGS) revenue rose 24% YoY and now accounts for nearly one‑third of clinical revenue. Average revenue per clinical test increased 3% to $476, reflecting a shift toward higher‑value tests such as NGS.
The company reaffirmed its full‑year 2025 guidance, projecting revenue of $720 million to $726 million, a net loss of $116 million to $108 million, and adjusted EBITDA of $41 million to $44 million. For the quarter, NeoGenomics recorded a net loss of $27 million and positive adjusted EBITDA of $12.2 million, down 9% from the prior quarter. Operating expenses rose 12% to $107 million, largely due to $7.1 million in impairment charges related to the planned sale of Trapelo.
NeoGenomics highlighted that clinical test volumes increased 15% and that NGS growth outpaced the broader market, underscoring the company’s focus on high‑margin, high‑volume oncology diagnostics. The company also noted that its average revenue per test rose, driven by a mix shift toward NGS and other high‑value assays. These metrics suggest continued momentum in the community oncology channel.
The company scheduled a webcast and conference call to discuss the results at 8:30 a.m. Eastern Time on Tuesday, October 28, 2025. Management expressed confidence that the fourth‑quarter performance will build on the current momentum and that the company will enter 2026 with increased momentum.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.